Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

Item
http://www.wikidata.org/entity/Q48070812
Deep molecular responses for treatment-free remission in chronic myeloid leukemiaHow could patient reported outcomes improve patient management in chronic myeloid leukemia?Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid LeukemiaA nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study
P2860

Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

Item
http://www.wikidata.org/entity/Q48070812
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Impact of low-grade adverse ev ...... ous leukemia in chronic phase.
@en
Impact of low-grade adverse ev ...... ous leukemia in chronic phase.
@nl
type
label
Impact of low-grade adverse ev ...... ous leukemia in chronic phase.
@en
Impact of low-grade adverse ev ...... ous leukemia in chronic phase.
@nl
prefLabel
Impact of low-grade adverse ev ...... ous leukemia in chronic phase.
@en
Impact of low-grade adverse ev ...... ous leukemia in chronic phase.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Impact of low-grade adverse ev ...... ous leukemia in chronic phase.
@en
P2093
P304
P31
P356
10.1185/03007995.2014.944973
P407
P433
P478
P50
P577
P698
P921